MINAPHARM Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
MINAPHARM Pharmaceuticals's earnings have been declining at an average annual rate of -2.3%, while the Pharmaceuticals industry saw earnings growing at 15.1% annually. Revenues have been growing at an average rate of 16.3% per year.
Key information
-2.3%
Earnings growth rate
-1.3%
EPS growth rate
Pharmaceuticals Industry Growth
9.8%
Revenue growth rate
16.3%
Return on equity
-5.3%
Net Margin
-7.0%
Last Earnings Update
30 Jun 2024
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How MINAPHARM Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
CASE:MIPH Revenue, expenses and earnings (EGP Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Jun 24
3,916
-273
701
156
31 Mar 24
3,904
-87
739
154
31 Dec 23
3,892
-55
726
151
30 Sep 23
3,943
210
673
125
30 Jun 23
4,003
480
603
98
31 Mar 23
3,794
529
525
76
31 Dec 22
3,621
590
472
59
30 Sep 22
3,442
544
456
46
30 Jun 22
3,212
467
429
46
31 Mar 22
3,032
454
401
47
31 Dec 21
3,005
448
386
46
30 Sep 21
2,918
422
377
53
30 Jun 21
2,754
398
357
46
31 Mar 21
2,583
325
337
43
31 Dec 20
2,361
285
327
39
30 Sep 20
2,200
271
327
40
30 Jun 20
2,115
216
312
39
31 Mar 20
2,080
174
319
40
31 Dec 19
2,051
141
311
39
30 Sep 19
1,917
86
310
48
30 Jun 19
1,936
67
304
52
31 Mar 19
1,948
81
306
59
31 Dec 18
1,919
116
291
65
30 Sep 18
1,928
156
258
68
30 Jun 18
1,820
186
247
65
31 Mar 18
1,717
198
220
54
31 Dec 17
1,646
175
209
53
30 Sep 17
1,493
65
203
46
30 Jun 17
1,325
55
193
41
31 Mar 17
1,190
35
179
46
31 Dec 16
1,035
33
173
39
30 Sep 16
1,023
86
152
32
30 Jun 16
1,019
97
146
34
31 Mar 16
1,001
110
145
29
31 Dec 15
966
83
140
26
30 Sep 15
916
85
138
29
30 Jun 15
885
61
137
28
31 Mar 15
861
57
128
26
31 Dec 14
830
49
126
29
30 Sep 14
807
75
121
24
30 Jun 14
772
71
114
29
31 Mar 14
728
69
116
28
31 Dec 13
712
81
114
25
Quality Earnings: MIPH is currently unprofitable.
Growing Profit Margin: MIPH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MIPH is unprofitable, and losses have increased over the past 5 years at a rate of 2.3% per year.
Accelerating Growth: Unable to compare MIPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MIPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (26.9%).
Return on Equity
High ROE: MIPH has a negative Return on Equity (-5.26%), as it is currently unprofitable.